nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—ABCG2—Dactinomycin—testicular cancer	0.107	0.128	CbGbCtD
Vismodegib—ABCG2—Carboplatin—testicular cancer	0.0717	0.0862	CbGbCtD
Vismodegib—CYP2C8—Ifosfamide—testicular cancer	0.0671	0.0806	CbGbCtD
Vismodegib—ABCG2—Cisplatin—testicular cancer	0.0612	0.0736	CbGbCtD
Vismodegib—ABCG2—Etoposide—testicular cancer	0.0602	0.0723	CbGbCtD
Vismodegib—CYP2C19—Ifosfamide—testicular cancer	0.0563	0.0677	CbGbCtD
Vismodegib—CYP2C9—Ifosfamide—testicular cancer	0.0468	0.0562	CbGbCtD
Vismodegib—ABCG2—Doxorubicin—testicular cancer	0.041	0.0493	CbGbCtD
Vismodegib—ABCG2—Methotrexate—testicular cancer	0.0398	0.0478	CbGbCtD
Vismodegib—ABCB1—Dactinomycin—testicular cancer	0.0384	0.0462	CbGbCtD
Vismodegib—CYP2C8—Etoposide—testicular cancer	0.032	0.0385	CbGbCtD
Vismodegib—ALB—Methotrexate—testicular cancer	0.0274	0.0329	CbGbCtD
Vismodegib—CYP3A4—Ifosfamide—testicular cancer	0.0272	0.0327	CbGbCtD
Vismodegib—ABCB1—Vinblastine—testicular cancer	0.0241	0.029	CbGbCtD
Vismodegib—CYP2C9—Cisplatin—testicular cancer	0.0228	0.0274	CbGbCtD
Vismodegib—ABCB1—Cisplatin—testicular cancer	0.0221	0.0265	CbGbCtD
Vismodegib—ABCB1—Etoposide—testicular cancer	0.0217	0.0261	CbGbCtD
Vismodegib—ABCB1—Doxorubicin—testicular cancer	0.0148	0.0178	CbGbCtD
Vismodegib—CYP3A4—Vinblastine—testicular cancer	0.0144	0.0173	CbGbCtD
Vismodegib—ABCB1—Methotrexate—testicular cancer	0.0143	0.0172	CbGbCtD
Vismodegib—CYP3A4—Etoposide—testicular cancer	0.013	0.0156	CbGbCtD
Vismodegib—Sorafenib—STK10—testicular cancer	0.00922	0.736	CrCbGaD
Vismodegib—CYP3A4—Doxorubicin—testicular cancer	0.00886	0.0107	CbGbCtD
Vismodegib—SHH—embryo—testicular cancer	0.00681	0.22	CbGeAlD
Vismodegib—SHH—Validated transcriptional targets of TAp63 isoforms—TFAP2C—testicular cancer	0.00488	0.291	CbGpPWpGaD
Vismodegib—SMO—embryo—testicular cancer	0.00476	0.154	CbGeAlD
Vismodegib—SMO—seminal vesicle—testicular cancer	0.00447	0.144	CbGeAlD
Vismodegib—Sorafenib—KIT—testicular cancer	0.00331	0.264	CrCbGaD
Vismodegib—SMO—female gonad—testicular cancer	0.00263	0.0848	CbGeAlD
Vismodegib—Neoplasm malignant—Chlorambucil—testicular cancer	0.00252	0.0233	CcSEcCtD
Vismodegib—Amenorrhoea—Chlorambucil—testicular cancer	0.00245	0.0226	CcSEcCtD
Vismodegib—SMO—testis—testicular cancer	0.00233	0.0752	CbGeAlD
Vismodegib—SHH—Ectoderm Differentiation—TFAP2C—testicular cancer	0.0023	0.138	CbGpPWpGaD
Vismodegib—SMO—lymph node—testicular cancer	0.00169	0.0545	CbGeAlD
Vismodegib—Neoplasm malignant—Ifosfamide—testicular cancer	0.00166	0.0154	CcSEcCtD
Vismodegib—Musculoskeletal chest pain—Epirubicin—testicular cancer	0.00162	0.015	CcSEcCtD
Vismodegib—Amenorrhoea—Ifosfamide—testicular cancer	0.00162	0.015	CcSEcCtD
Vismodegib—Ageusia—Cisplatin—testicular cancer	0.00151	0.014	CcSEcCtD
Vismodegib—Musculoskeletal chest pain—Doxorubicin—testicular cancer	0.0015	0.0139	CcSEcCtD
Vismodegib—Pain—Carboplatin—testicular cancer	0.00127	0.0118	CcSEcCtD
Vismodegib—Azotaemia—Methotrexate—testicular cancer	0.00126	0.0117	CcSEcCtD
Vismodegib—SHH—Differentiation Pathway—KITLG—testicular cancer	0.0012	0.0715	CbGpPWpGaD
Vismodegib—ABCG2—seminal vesicle—testicular cancer	0.00117	0.0378	CbGeAlD
Vismodegib—Phosphatase alkaline increased—Etoposide—testicular cancer	0.00112	0.0104	CcSEcCtD
Vismodegib—Pain in extremity—Ifosfamide—testicular cancer	0.00103	0.00954	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Dactinomycin—testicular cancer	0.00101	0.00938	CcSEcCtD
Vismodegib—Alopecia—Chlorambucil—testicular cancer	0.000954	0.00882	CcSEcCtD
Vismodegib—Weight decreased—Bleomycin—testicular cancer	0.000944	0.00873	CcSEcCtD
Vismodegib—Hypokalaemia—Ifosfamide—testicular cancer	0.000939	0.00868	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Etoposide—testicular cancer	0.000937	0.00866	CcSEcCtD
Vismodegib—Breast disorder—Ifosfamide—testicular cancer	0.000932	0.00862	CcSEcCtD
Vismodegib—Hyponatraemia—Cisplatin—testicular cancer	0.000893	0.00826	CcSEcCtD
Vismodegib—ALB—testis—testicular cancer	0.000893	0.0288	CbGeAlD
Vismodegib—Alopecia—Vinblastine—testicular cancer	0.000874	0.00808	CcSEcCtD
Vismodegib—Dehydration—Cisplatin—testicular cancer	0.000827	0.00765	CcSEcCtD
Vismodegib—SHH—Differentiation Pathway—KIT—testicular cancer	0.000817	0.0488	CbGpPWpGaD
Vismodegib—Hypokalaemia—Cisplatin—testicular cancer	0.00081	0.00749	CcSEcCtD
Vismodegib—Breast disorder—Cisplatin—testicular cancer	0.000804	0.00743	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Cisplatin—testicular cancer	0.000801	0.00741	CcSEcCtD
Vismodegib—Ageusia—Epirubicin—testicular cancer	0.000777	0.00718	CcSEcCtD
Vismodegib—Alopecia—Bleomycin—testicular cancer	0.000738	0.00682	CcSEcCtD
Vismodegib—ORM1—lymph node—testicular cancer	0.000738	0.0238	CbGeAlD
Vismodegib—Neoplasm malignant—Epirubicin—testicular cancer	0.000737	0.00681	CcSEcCtD
Vismodegib—Ageusia—Doxorubicin—testicular cancer	0.000719	0.00665	CcSEcCtD
Vismodegib—Amenorrhoea—Epirubicin—testicular cancer	0.000716	0.00662	CcSEcCtD
Vismodegib—Hepatic enzyme increased—Methotrexate—testicular cancer	0.000711	0.00657	CcSEcCtD
Vismodegib—Connective tissue disorder—Ifosfamide—testicular cancer	0.000701	0.00649	CcSEcCtD
Vismodegib—SHH—GPCR ligand binding—INSL3—testicular cancer	0.000691	0.0412	CbGpPWpGaD
Vismodegib—Alopecia—Dactinomycin—testicular cancer	0.000688	0.00636	CcSEcCtD
Vismodegib—ABCG2—female gonad—testicular cancer	0.000688	0.0222	CbGeAlD
Vismodegib—Neoplasm malignant—Doxorubicin—testicular cancer	0.000682	0.00631	CcSEcCtD
Vismodegib—Dyspepsia—Chlorambucil—testicular cancer	0.000675	0.00624	CcSEcCtD
Vismodegib—Decreased appetite—Chlorambucil—testicular cancer	0.000667	0.00616	CcSEcCtD
Vismodegib—Amenorrhoea—Doxorubicin—testicular cancer	0.000663	0.00613	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.000662	0.00612	CcSEcCtD
Vismodegib—Fatigue—Chlorambucil—testicular cancer	0.000661	0.00611	CcSEcCtD
Vismodegib—Pain—Chlorambucil—testicular cancer	0.000656	0.00606	CcSEcCtD
Vismodegib—SMO—GPCR ligand binding—INSL3—testicular cancer	0.000655	0.0391	CbGpPWpGaD
Vismodegib—ALB—lymph node—testicular cancer	0.000647	0.0209	CbGeAlD
Vismodegib—Musculoskeletal pain—Epirubicin—testicular cancer	0.000637	0.00589	CcSEcCtD
Vismodegib—Alopecia—Ifosfamide—testicular cancer	0.000631	0.00583	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Epirubicin—testicular cancer	0.000629	0.00582	CcSEcCtD
Vismodegib—CYP2C8—testis—testicular cancer	0.000627	0.0203	CbGeAlD
Vismodegib—Gastrointestinal pain—Chlorambucil—testicular cancer	0.000627	0.0058	CcSEcCtD
Vismodegib—Malnutrition—Ifosfamide—testicular cancer	0.000621	0.00575	CcSEcCtD
Vismodegib—Myalgia—Bleomycin—testicular cancer	0.000619	0.00572	CcSEcCtD
Vismodegib—ABCB1—embryo—testicular cancer	0.000615	0.0198	CbGeAlD
Vismodegib—Decreased appetite—Vinblastine—testicular cancer	0.000611	0.00565	CcSEcCtD
Vismodegib—ABCG2—testis—testicular cancer	0.00061	0.0197	CbGeAlD
Vismodegib—Abdominal pain—Chlorambucil—testicular cancer	0.000606	0.0056	CcSEcCtD
Vismodegib—Connective tissue disorder—Cisplatin—testicular cancer	0.000605	0.00559	CcSEcCtD
Vismodegib—Pain—Vinblastine—testicular cancer	0.000601	0.00556	CcSEcCtD
Vismodegib—Constipation—Vinblastine—testicular cancer	0.000601	0.00556	CcSEcCtD
Vismodegib—Blood urea increased—Epirubicin—testicular cancer	0.000594	0.00549	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.00059	0.0352	CbGpPWpGaD
Vismodegib—Musculoskeletal pain—Doxorubicin—testicular cancer	0.000589	0.00545	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Doxorubicin—testicular cancer	0.000582	0.00538	CcSEcCtD
Vismodegib—ABCB1—seminal vesicle—testicular cancer	0.000577	0.0186	CbGeAlD
Vismodegib—Myalgia—Dactinomycin—testicular cancer	0.000577	0.00534	CcSEcCtD
Vismodegib—Gastrointestinal pain—Vinblastine—testicular cancer	0.000575	0.00531	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000559	0.0334	CbGpPWpGaD
Vismodegib—Abdominal pain—Vinblastine—testicular cancer	0.000555	0.00514	CcSEcCtD
Vismodegib—Asthenia—Chlorambucil—testicular cancer	0.00055	0.00509	CcSEcCtD
Vismodegib—Blood urea increased—Doxorubicin—testicular cancer	0.00055	0.00508	CcSEcCtD
Vismodegib—Alopecia—Cisplatin—testicular cancer	0.000544	0.00503	CcSEcCtD
Vismodegib—Pruritus—Chlorambucil—testicular cancer	0.000542	0.00502	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.000541	0.005	CcSEcCtD
Vismodegib—Malnutrition—Cisplatin—testicular cancer	0.000536	0.00495	CcSEcCtD
Vismodegib—Myalgia—Ifosfamide—testicular cancer	0.000529	0.00489	CcSEcCtD
Vismodegib—Arthralgia—Ifosfamide—testicular cancer	0.000529	0.00489	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.000525	0.00486	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Epirubicin—testicular cancer	0.000525	0.00486	CcSEcCtD
Vismodegib—Diarrhoea—Chlorambucil—testicular cancer	0.000525	0.00485	CcSEcCtD
Vismodegib—Decreased appetite—Bleomycin—testicular cancer	0.000516	0.00477	CcSEcCtD
Vismodegib—Muscle spasms—Cisplatin—testicular cancer	0.000515	0.00476	CcSEcCtD
Vismodegib—Pain—Bleomycin—testicular cancer	0.000507	0.00469	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.000504	0.00466	CcSEcCtD
Vismodegib—Asthenia—Vinblastine—testicular cancer	0.000504	0.00466	CcSEcCtD
Vismodegib—Alopecia—Etoposide—testicular cancer	0.000498	0.00461	CcSEcCtD
Vismodegib—Nervous system disorder—Ifosfamide—testicular cancer	0.000497	0.0046	CcSEcCtD
Vismodegib—Skin disorder—Ifosfamide—testicular cancer	0.000493	0.00455	CcSEcCtD
Vismodegib—Vomiting—Chlorambucil—testicular cancer	0.000487	0.00451	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Doxorubicin—testicular cancer	0.000486	0.00449	CcSEcCtD
Vismodegib—Decreased appetite—Dactinomycin—testicular cancer	0.000481	0.00445	CcSEcCtD
Vismodegib—Diarrhoea—Vinblastine—testicular cancer	0.000481	0.00444	CcSEcCtD
Vismodegib—Dysgeusia—Etoposide—testicular cancer	0.000481	0.00444	CcSEcCtD
Vismodegib—Fatigue—Dactinomycin—testicular cancer	0.000477	0.00441	CcSEcCtD
Vismodegib—Back pain—Etoposide—testicular cancer	0.000475	0.00439	CcSEcCtD
Vismodegib—Pain—Dactinomycin—testicular cancer	0.000473	0.00438	CcSEcCtD
Vismodegib—Muscle spasms—Etoposide—testicular cancer	0.000472	0.00436	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.000462	0.00427	CcSEcCtD
Vismodegib—Hyponatraemia—Epirubicin—testicular cancer	0.000459	0.00424	CcSEcCtD
Vismodegib—Pain in extremity—Epirubicin—testicular cancer	0.000457	0.00422	CcSEcCtD
Vismodegib—Myalgia—Cisplatin—testicular cancer	0.000456	0.00422	CcSEcCtD
Vismodegib—Nausea—Chlorambucil—testicular cancer	0.000455	0.00421	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000453	0.00419	CcSEcCtD
Vismodegib—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000453	0.00418	CcSEcCtD
Vismodegib—Vomiting—Vinblastine—testicular cancer	0.000447	0.00413	CcSEcCtD
Vismodegib—ABCG2—lymph node—testicular cancer	0.000442	0.0143	CbGeAlD
Vismodegib—Breast disorder—Methotrexate—testicular cancer	0.000441	0.00408	CcSEcCtD
Vismodegib—Decreased appetite—Ifosfamide—testicular cancer	0.000441	0.00408	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000438	0.00405	CcSEcCtD
Vismodegib—Abdominal pain—Dactinomycin—testicular cancer	0.000438	0.00405	CcSEcCtD
Vismodegib—Fatigue—Ifosfamide—testicular cancer	0.000437	0.00404	CcSEcCtD
Vismodegib—Constipation—Ifosfamide—testicular cancer	0.000434	0.00401	CcSEcCtD
Vismodegib—Pain—Ifosfamide—testicular cancer	0.000434	0.00401	CcSEcCtD
Vismodegib—Nervous system disorder—Cisplatin—testicular cancer	0.000429	0.00396	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000428	0.0256	CbGpPWpGaD
Vismodegib—Asthenia—Bleomycin—testicular cancer	0.000426	0.00394	CcSEcCtD
Vismodegib—Dehydration—Epirubicin—testicular cancer	0.000425	0.00393	CcSEcCtD
Vismodegib—Skin disorder—Cisplatin—testicular cancer	0.000425	0.00393	CcSEcCtD
Vismodegib—Hyponatraemia—Doxorubicin—testicular cancer	0.000424	0.00392	CcSEcCtD
Vismodegib—Pain in extremity—Doxorubicin—testicular cancer	0.000423	0.00391	CcSEcCtD
Vismodegib—Pruritus—Bleomycin—testicular cancer	0.00042	0.00388	CcSEcCtD
Vismodegib—Nausea—Vinblastine—testicular cancer	0.000417	0.00386	CcSEcCtD
Vismodegib—ABCB1—gonad—testicular cancer	0.000417	0.0135	CbGeAlD
Vismodegib—Abdominal pain upper—Epirubicin—testicular cancer	0.000417	0.00386	CcSEcCtD
Vismodegib—Hypokalaemia—Epirubicin—testicular cancer	0.000416	0.00384	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000415	0.00384	CcSEcCtD
Vismodegib—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000415	0.00383	CcSEcCtD
Vismodegib—Breast disorder—Epirubicin—testicular cancer	0.000413	0.00382	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000411	0.0038	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000406	0.0243	CbGpPWpGaD
Vismodegib—Abdominal pain—Ifosfamide—testicular cancer	0.000401	0.00371	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000398	0.00368	CcSEcCtD
Vismodegib—Asthenia—Dactinomycin—testicular cancer	0.000397	0.00367	CcSEcCtD
Vismodegib—Dehydration—Doxorubicin—testicular cancer	0.000393	0.00363	CcSEcCtD
Vismodegib—Skin disorder—Etoposide—testicular cancer	0.000389	0.0036	CcSEcCtD
Vismodegib—Abdominal pain upper—Doxorubicin—testicular cancer	0.000386	0.00357	CcSEcCtD
Vismodegib—Hypokalaemia—Doxorubicin—testicular cancer	0.000385	0.00356	CcSEcCtD
Vismodegib—Breast disorder—Doxorubicin—testicular cancer	0.000382	0.00353	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000381	0.00352	CcSEcCtD
Vismodegib—Decreased appetite—Cisplatin—testicular cancer	0.00038	0.00351	CcSEcCtD
Vismodegib—Diarrhoea—Dactinomycin—testicular cancer	0.000379	0.0035	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000377	0.00349	CcSEcCtD
Vismodegib—Vomiting—Bleomycin—testicular cancer	0.000377	0.00349	CcSEcCtD
Vismodegib—Rash—Bleomycin—testicular cancer	0.000374	0.00346	CcSEcCtD
Vismodegib—Pain—Cisplatin—testicular cancer	0.000374	0.00346	CcSEcCtD
Vismodegib—Dermatitis—Bleomycin—testicular cancer	0.000374	0.00346	CcSEcCtD
Vismodegib—Asthenia—Ifosfamide—testicular cancer	0.000364	0.00336	CcSEcCtD
Vismodegib—Pruritus—Ifosfamide—testicular cancer	0.000359	0.00332	CcSEcCtD
Vismodegib—Weight decreased—Epirubicin—testicular cancer	0.000357	0.0033	CcSEcCtD
Vismodegib—SHH—Signaling by GPCR—INSL3—testicular cancer	0.000354	0.0212	CbGpPWpGaD
Vismodegib—Nausea—Bleomycin—testicular cancer	0.000352	0.00326	CcSEcCtD
Vismodegib—Vomiting—Dactinomycin—testicular cancer	0.000352	0.00325	CcSEcCtD
Vismodegib—Rash—Dactinomycin—testicular cancer	0.000349	0.00323	CcSEcCtD
Vismodegib—Decreased appetite—Etoposide—testicular cancer	0.000348	0.00322	CcSEcCtD
Vismodegib—Diarrhoea—Ifosfamide—testicular cancer	0.000347	0.00321	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Etoposide—testicular cancer	0.000346	0.0032	CcSEcCtD
Vismodegib—Fatigue—Etoposide—testicular cancer	0.000345	0.00319	CcSEcCtD
Vismodegib—Constipation—Etoposide—testicular cancer	0.000343	0.00317	CcSEcCtD
Vismodegib—Pain—Etoposide—testicular cancer	0.000343	0.00317	CcSEcCtD
Vismodegib—ABCB1—female gonad—testicular cancer	0.000339	0.0109	CbGeAlD
Vismodegib—SMO—Signaling by GPCR—INSL3—testicular cancer	0.000336	0.0201	CbGpPWpGaD
Vismodegib—Weight decreased—Doxorubicin—testicular cancer	0.000331	0.00306	CcSEcCtD
Vismodegib—Nausea—Dactinomycin—testicular cancer	0.000329	0.00304	CcSEcCtD
Vismodegib—Gastrointestinal pain—Etoposide—testicular cancer	0.000328	0.00303	CcSEcCtD
Vismodegib—Vomiting—Ifosfamide—testicular cancer	0.000322	0.00298	CcSEcCtD
Vismodegib—Rash—Ifosfamide—testicular cancer	0.00032	0.00296	CcSEcCtD
Vismodegib—Dermatitis—Ifosfamide—testicular cancer	0.000319	0.00295	CcSEcCtD
Vismodegib—Abdominal pain—Etoposide—testicular cancer	0.000317	0.00293	CcSEcCtD
Vismodegib—Asthenia—Cisplatin—testicular cancer	0.000314	0.0029	CcSEcCtD
Vismodegib—Connective tissue disorder—Epirubicin—testicular cancer	0.000311	0.00287	CcSEcCtD
Vismodegib—Nausea—Ifosfamide—testicular cancer	0.000301	0.00279	CcSEcCtD
Vismodegib—ABCB1—testis—testicular cancer	0.000301	0.00971	CbGeAlD
Vismodegib—Diarrhoea—Cisplatin—testicular cancer	0.000299	0.00277	CcSEcCtD
Vismodegib—Alopecia—Methotrexate—testicular cancer	0.000298	0.00276	CcSEcCtD
Vismodegib—Malnutrition—Methotrexate—testicular cancer	0.000294	0.00272	CcSEcCtD
Vismodegib—Dysgeusia—Methotrexate—testicular cancer	0.000288	0.00266	CcSEcCtD
Vismodegib—Asthenia—Etoposide—testicular cancer	0.000287	0.00266	CcSEcCtD
Vismodegib—Connective tissue disorder—Doxorubicin—testicular cancer	0.000287	0.00266	CcSEcCtD
Vismodegib—Back pain—Methotrexate—testicular cancer	0.000284	0.00263	CcSEcCtD
Vismodegib—Pruritus—Etoposide—testicular cancer	0.000283	0.00262	CcSEcCtD
Vismodegib—Alopecia—Epirubicin—testicular cancer	0.000279	0.00258	CcSEcCtD
Vismodegib—Vomiting—Cisplatin—testicular cancer	0.000278	0.00257	CcSEcCtD
Vismodegib—Rash—Cisplatin—testicular cancer	0.000276	0.00255	CcSEcCtD
Vismodegib—Dermatitis—Cisplatin—testicular cancer	0.000275	0.00255	CcSEcCtD
Vismodegib—Malnutrition—Epirubicin—testicular cancer	0.000275	0.00254	CcSEcCtD
Vismodegib—Diarrhoea—Etoposide—testicular cancer	0.000274	0.00253	CcSEcCtD
Vismodegib—Dysgeusia—Epirubicin—testicular cancer	0.000269	0.00249	CcSEcCtD
Vismodegib—Back pain—Epirubicin—testicular cancer	0.000266	0.00246	CcSEcCtD
Vismodegib—Muscle spasms—Epirubicin—testicular cancer	0.000265	0.00245	CcSEcCtD
Vismodegib—Nausea—Cisplatin—testicular cancer	0.00026	0.0024	CcSEcCtD
Vismodegib—Alopecia—Doxorubicin—testicular cancer	0.000258	0.00239	CcSEcCtD
Vismodegib—Vomiting—Etoposide—testicular cancer	0.000255	0.00235	CcSEcCtD
Vismodegib—Malnutrition—Doxorubicin—testicular cancer	0.000255	0.00235	CcSEcCtD
Vismodegib—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000254	0.0152	CbGpPWpGaD
Vismodegib—Rash—Etoposide—testicular cancer	0.000253	0.00234	CcSEcCtD
Vismodegib—Dermatitis—Etoposide—testicular cancer	0.000252	0.00233	CcSEcCtD
Vismodegib—Arthralgia—Methotrexate—testicular cancer	0.00025	0.00231	CcSEcCtD
Vismodegib—Myalgia—Methotrexate—testicular cancer	0.00025	0.00231	CcSEcCtD
Vismodegib—Dysgeusia—Doxorubicin—testicular cancer	0.000249	0.0023	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000249	0.0023	CcSEcCtD
Vismodegib—Back pain—Doxorubicin—testicular cancer	0.000246	0.00228	CcSEcCtD
Vismodegib—Muscle spasms—Doxorubicin—testicular cancer	0.000245	0.00226	CcSEcCtD
Vismodegib—Nausea—Etoposide—testicular cancer	0.000238	0.0022	CcSEcCtD
Vismodegib—Nervous system disorder—Methotrexate—testicular cancer	0.000235	0.00218	CcSEcCtD
Vismodegib—Arthralgia—Epirubicin—testicular cancer	0.000234	0.00217	CcSEcCtD
Vismodegib—Myalgia—Epirubicin—testicular cancer	0.000234	0.00217	CcSEcCtD
Vismodegib—Skin disorder—Methotrexate—testicular cancer	0.000233	0.00215	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000233	0.00215	CcSEcCtD
Vismodegib—CYP2C19—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000227	0.0136	CbGpPWpGaD
Vismodegib—Nervous system disorder—Epirubicin—testicular cancer	0.00022	0.00204	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000219	0.00202	CcSEcCtD
Vismodegib—Skin disorder—Epirubicin—testicular cancer	0.000218	0.00202	CcSEcCtD
Vismodegib—ABCB1—lymph node—testicular cancer	0.000218	0.00704	CbGeAlD
Vismodegib—Myalgia—Doxorubicin—testicular cancer	0.000217	0.002	CcSEcCtD
Vismodegib—Arthralgia—Doxorubicin—testicular cancer	0.000217	0.002	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000215	0.00199	CcSEcCtD
Vismodegib—Dyspepsia—Methotrexate—testicular cancer	0.000211	0.00195	CcSEcCtD
Vismodegib—SHH—Signaling Pathways—INSL3—testicular cancer	0.000209	0.0125	CbGpPWpGaD
Vismodegib—Decreased appetite—Methotrexate—testicular cancer	0.000209	0.00193	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000207	0.00192	CcSEcCtD
Vismodegib—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000207	0.0124	CbGpPWpGaD
Vismodegib—Fatigue—Methotrexate—testicular cancer	0.000207	0.00191	CcSEcCtD
Vismodegib—Pain—Methotrexate—testicular cancer	0.000205	0.0019	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000205	0.00189	CcSEcCtD
Vismodegib—Nervous system disorder—Doxorubicin—testicular cancer	0.000204	0.00188	CcSEcCtD
Vismodegib—Skin disorder—Doxorubicin—testicular cancer	0.000202	0.00187	CcSEcCtD
Vismodegib—SMO—Signaling Pathways—INSL3—testicular cancer	0.000198	0.0118	CbGpPWpGaD
Vismodegib—Dyspepsia—Epirubicin—testicular cancer	0.000198	0.00183	CcSEcCtD
Vismodegib—Gastrointestinal pain—Methotrexate—testicular cancer	0.000196	0.00181	CcSEcCtD
Vismodegib—Decreased appetite—Epirubicin—testicular cancer	0.000195	0.0018	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000194	0.00179	CcSEcCtD
Vismodegib—Fatigue—Epirubicin—testicular cancer	0.000194	0.00179	CcSEcCtD
Vismodegib—Constipation—Epirubicin—testicular cancer	0.000192	0.00178	CcSEcCtD
Vismodegib—Pain—Epirubicin—testicular cancer	0.000192	0.00178	CcSEcCtD
Vismodegib—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000191	0.0114	CbGpPWpGaD
Vismodegib—Abdominal pain—Methotrexate—testicular cancer	0.00019	0.00175	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000189	0.00175	CcSEcCtD
Vismodegib—ALB—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000186	0.0111	CbGpPWpGaD
Vismodegib—Gastrointestinal pain—Epirubicin—testicular cancer	0.000184	0.0017	CcSEcCtD
Vismodegib—Dyspepsia—Doxorubicin—testicular cancer	0.000183	0.00169	CcSEcCtD
Vismodegib—Decreased appetite—Doxorubicin—testicular cancer	0.000181	0.00167	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000179	0.00166	CcSEcCtD
Vismodegib—Fatigue—Doxorubicin—testicular cancer	0.000179	0.00166	CcSEcCtD
Vismodegib—Pain—Doxorubicin—testicular cancer	0.000178	0.00164	CcSEcCtD
Vismodegib—Constipation—Doxorubicin—testicular cancer	0.000178	0.00164	CcSEcCtD
Vismodegib—Abdominal pain—Epirubicin—testicular cancer	0.000177	0.00164	CcSEcCtD
Vismodegib—Asthenia—Methotrexate—testicular cancer	0.000172	0.00159	CcSEcCtD
Vismodegib—Gastrointestinal pain—Doxorubicin—testicular cancer	0.00017	0.00157	CcSEcCtD
Vismodegib—Pruritus—Methotrexate—testicular cancer	0.00017	0.00157	CcSEcCtD
Vismodegib—Abdominal pain—Doxorubicin—testicular cancer	0.000164	0.00152	CcSEcCtD
Vismodegib—Diarrhoea—Methotrexate—testicular cancer	0.000164	0.00152	CcSEcCtD
Vismodegib—Asthenia—Epirubicin—testicular cancer	0.000161	0.00149	CcSEcCtD
Vismodegib—Pruritus—Epirubicin—testicular cancer	0.000159	0.00147	CcSEcCtD
Vismodegib—Diarrhoea—Epirubicin—testicular cancer	0.000154	0.00142	CcSEcCtD
Vismodegib—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000154	0.00917	CbGpPWpGaD
Vismodegib—Vomiting—Methotrexate—testicular cancer	0.000153	0.00141	CcSEcCtD
Vismodegib—Rash—Methotrexate—testicular cancer	0.000151	0.0014	CcSEcCtD
Vismodegib—Dermatitis—Methotrexate—testicular cancer	0.000151	0.0014	CcSEcCtD
Vismodegib—Asthenia—Doxorubicin—testicular cancer	0.000149	0.00138	CcSEcCtD
Vismodegib—Pruritus—Doxorubicin—testicular cancer	0.000147	0.00136	CcSEcCtD
Vismodegib—Vomiting—Epirubicin—testicular cancer	0.000143	0.00132	CcSEcCtD
Vismodegib—Nausea—Methotrexate—testicular cancer	0.000143	0.00132	CcSEcCtD
Vismodegib—Diarrhoea—Doxorubicin—testicular cancer	0.000142	0.00131	CcSEcCtD
Vismodegib—Rash—Epirubicin—testicular cancer	0.000142	0.00131	CcSEcCtD
Vismodegib—Dermatitis—Epirubicin—testicular cancer	0.000141	0.00131	CcSEcCtD
Vismodegib—Nausea—Epirubicin—testicular cancer	0.000133	0.00123	CcSEcCtD
Vismodegib—Vomiting—Doxorubicin—testicular cancer	0.000132	0.00122	CcSEcCtD
Vismodegib—Rash—Doxorubicin—testicular cancer	0.000131	0.00121	CcSEcCtD
Vismodegib—Dermatitis—Doxorubicin—testicular cancer	0.000131	0.00121	CcSEcCtD
Vismodegib—Nausea—Doxorubicin—testicular cancer	0.000123	0.00114	CcSEcCtD
Vismodegib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000103	0.00617	CbGpPWpGaD
Vismodegib—SHH—Disease—H2AFZ—testicular cancer	9.57e-05	0.00571	CbGpPWpGaD
Vismodegib—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	9.47e-05	0.00566	CbGpPWpGaD
Vismodegib—CYP2C8—Biological oxidations—HPGDS—testicular cancer	9.47e-05	0.00565	CbGpPWpGaD
Vismodegib—SHH—Disease—KITLG—testicular cancer	8.8e-05	0.00526	CbGpPWpGaD
Vismodegib—CYP2C19—Biological oxidations—HPGDS—testicular cancer	8.45e-05	0.00505	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	8.3e-05	0.00496	CbGpPWpGaD
Vismodegib—CYP2C9—Biological oxidations—HPGDS—testicular cancer	7.71e-05	0.0046	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	7.59e-05	0.00453	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—H2AFZ—testicular cancer	6.7e-05	0.004	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—STK11—testicular cancer	6.66e-05	0.00398	CbGpPWpGaD
Vismodegib—SHH—Disease—FGFR3—testicular cancer	6.54e-05	0.00391	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—H2AFZ—testicular cancer	6.35e-05	0.00379	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—STK11—testicular cancer	6.32e-05	0.00377	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—KITLG—testicular cancer	6.17e-05	0.00368	CbGpPWpGaD
Vismodegib—SHH—Disease—KIT—testicular cancer	6.01e-05	0.00359	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—KITLG—testicular cancer	5.84e-05	0.00349	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	5.51e-05	0.00329	CbGpPWpGaD
Vismodegib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	5.08e-05	0.00304	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—FGFR3—testicular cancer	4.58e-05	0.00274	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—FGFR3—testicular cancer	4.34e-05	0.00259	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—KIT—testicular cancer	4.21e-05	0.00251	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—KIT—testicular cancer	3.99e-05	0.00238	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.64e-05	0.00217	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.62e-05	0.00216	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.25e-05	0.00194	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.96e-05	0.00177	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—HPGDS—testicular cancer	2.61e-05	0.00156	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—STK11—testicular cancer	1.9e-05	0.00113	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—HPGDS—testicular cancer	1.62e-05	0.000967	CbGpPWpGaD
Vismodegib—ALB—Metabolism—HPGDS—testicular cancer	1.61e-05	0.000962	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—HPGDS—testicular cancer	1.45e-05	0.000863	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—HPGDS—testicular cancer	1.41e-05	0.000843	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—HPGDS—testicular cancer	1.32e-05	0.000787	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—STK11—testicular cancer	1.18e-05	0.000703	CbGpPWpGaD
Vismodegib—ALB—Metabolism—STK11—testicular cancer	1.17e-05	0.000699	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—STK11—testicular cancer	1.05e-05	0.000627	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—STK11—testicular cancer	1.03e-05	0.000612	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—STK11—testicular cancer	9.58e-06	0.000572	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—HPGDS—testicular cancer	8.69e-06	0.000519	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—STK11—testicular cancer	6.32e-06	0.000377	CbGpPWpGaD
